{"id":18812,"date":"2018-02-08T17:53:20","date_gmt":"2018-02-08T16:53:20","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=18812"},"modified":"2025-01-29T13:28:24","modified_gmt":"2025-01-29T12:28:24","slug":"february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share","status":"publish","type":"post","link":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/","title":{"rendered":"<span id=\"2018\" class=\"Postdate\">February 8, 2018<\/span> | Dermapharm Holding SE sets offer price at EUR 28.00 per share"},"content":{"rendered":"<style>\n.zur\u00fcckbutton:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #00225f;\n    margin-right: 7px;\n}\n.zur\u00fcckbutton:hover:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #d85710;\n    margin-right: 7px;\n}\n<\/style>\n<h1 style=\"text-align: justify;\">Ad hoc news<\/h1>\n<p><a class=\"zur\u00fcckbutton\" href=\"https:\/\/cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<p>&nbsp;<\/p>\n<h1>Dermapharm Holding SE sets offer price at EUR 28.00 per share<\/h1>\n<p>Gr\u00fcnwald, February 8, 2018 &#8211; Today, Dermapharm Holding SE (together with its consolidated\u00a0subsidiaries, &#8220;Dermapharm&#8221;, ISIN: DE000A2GS5D8) and the selling shareholder, Themis BeteiligungsAktiengesellschaft,\u00a0have set the offer price at EUR 28.00 per share.<br \/>\nIn total, all of the 13,455,000 offered shares in Dermapharm were placed. Thereof, 3,840,000 are newly\u00a0issued shares from a capital increase and 9,615,000 are shares from the holdings of the selling\u00a0shareholder, including 1,755,000 shares for over-allotments (\u201cGreenshoe Option\u201d). Assuming a full\u00a0exercise of the Greenshoe Option, total gross proceeds will amount to approx. EUR 377 million. Thereof,\u00a0gross proceeds of approx. EUR 108 million will be attributable to Dermapharm.<br \/>\nTrading in the shares on the regulated market (Prime Standard) of the Frankfurt Stock Exchange is\u00a0expected to commence on February 9, 2018. The securities identification number (WKN) is A2GS5D,\u00a0the international securities identification number (ISIN) is DE000A2GS5D8 and the trading symbol is\u00a0DMP.<\/p>\n<p><strong>Contact<\/strong><br \/>\ncometis AG<br \/>\nClaudius Krause<br \/>\nPhone: 0611-20585528<br \/>\nEmail: ir@dermapharm.de<\/p>\n<p>DISCLAIMER:<br \/>\nThese materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan.<br \/>\nThese materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities\u00a0(the \u201cSecurities\u201d) of Dermapharm Holding SE (the \u201cCompany\u201d) in the United States, Australia, Canada or any other\u00a0jurisdiction in which such offer or solicitation is unlawful. The Securities referred to herein may not be offered or\u00a0sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of\u00a0Australia, Canada or Japan subject to certain exceptions.<br \/>\nThe Securities of the Company may not be offered or sold in the United States absent registration or an exemption\u00a0from registration under the U.S. Securities Act of 1933, as amended (the \u201cSecurities Act\u201d). The Securities of the\u00a0Company have not been, and will not be, registered under the Securities Act. There will be no public offering of\u00a0the securities in the United States. Any sale in the United States of the Securities mentioned in this communication\u00a0will be made solely to \u201cqualified institutional buyers\u201d as defined in, and in reliance on, Rule 144A under the\u00a0Securities Act.<br \/>\nThis publication constitutes neither an offer to sell nor a solicitation to buy securities Dermapharm Holding SE.\u00a0The offer is being made solely by means of, and on the basis of, the published securities prospectus (including any\u00a0amendments thereto, if any). An investment decision regarding the publicly offered securities of Dermapharm\u00a0Holding SE should only be made on the basis of the securities prospectus. The securities prospectus has been\u00a0approved by the German Federal Financial Supervisory Authority (Bundesanstalt f\u00fcr Finanzdienstleistungsaufsicht\u00a0(BaFin)) and is available free of charge from Dermapharm Holding SE, Lil-Dagover-Ring 7, 82031 Gr\u00fcnwald,\u00a0Germany, or on the Dermapharm Holding SE website.\u00a0In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are\u00a0investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial\u00a0Promotion) Order 2005 (as amended) (the \u201cOrder\u201d) or (ii) are persons falling within Article 49(2)(a) through (d)\u00a0of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being\u00a0referred to as \u201cRelevant Persons\u201d). This document is directed only at Relevant Persons and must not be acted on\u00a0or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this<br \/>\ndocument relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.<br \/>\nIn connection with the placement of the offer shares Joh. Berenberg, Gossler &amp; Co. KG will act as the stabilization<br \/>\nmanager (the \u201cStabilization Manager\u201d) and may, as Stabilization Manager, and acting in accordance with legal<br \/>\nrequirements (Article 5 para. 4 and 5 of the Market Abuse Regulation (EU) No 596\/2014 in conjunction with<br \/>\nArticles 5 through 8 of the Commission Delegated Regulation (EU) 2016\/1052), make over-allotments and take<br \/>\nstabilization measures to support the market price of the Company\u2019s shares and thereby counteract any selling<br \/>\npressure.<br \/>\nThe Stabilization Manager is under no obligation to take any stabilization measures. Therefore, stabilization may<br \/>\nnot necessarily occur and may cease at any time. Such measures may be taken on the Frankfurt Stock Exchange<br \/>\n(Frankfurter Wertpapierb\u00f6rse) from the date when trading in the shares of the Company is commenced on the<br \/>\nregulated market segment (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse)<br \/>\nand must be terminated no later than 30 calendar days after this date (the \u201cStabilization Period\u201d). Stabilization<br \/>\ntransactions aim at supporting the market price of the Company\u2019s shares during the Stabilization Period. These<br \/>\nmeasures may result in the market price of the Company\u2019s shares being higher than would otherwise have been<br \/>\nthe case. Moreover, the market price may temporarily be at an unsustainable level.<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Post as PDF\" href=\"https:\/\/ir.dermapharm.de\/pdf\/20180208_AdHoc_Pricing_en.pdf\" target=\"_blank\" rel=\"noopener\">Post as PDF<\/a><\/div>\n<style>\n.leseprobe-archiv {\n    color: #00225f !important;\n    border-color: #00225f;\n    position: relative;\n    padding: 0.3em 1em;\n    border: 1px solid;\n    -webkit-border-radius: 3px;\n    -moz-border-radius: 3px;\n    border-radius: 3px;\n   -webkit-transition: all 0.2s;\n    -moz-transition: all 0.2s;\n    transition: all 0.2s;\n    padding:10px;\n    width: 19%;\n    text-align: center;\n    margin-right: 10px;\n    float:left;\n}\n.leseprobe-archiv:hover {\n    background-color: #eee;\n    border-color: #ffffff;\n    cursor: pointer;\n}\n<\/style>\n","protected":false},"excerpt":{"rendered":"<p>Ad hoc news to the archive &nbsp; Dermapharm Holding SE sets offer price at EUR 28.00 per share Gr\u00fcnwald, February 8, 2018 &#8211; Today, Dermapharm Holding SE (together with its consolidated\u00a0subsidiaries, &#8220;Dermapharm&#8221;, ISIN: DE000A2GS5D8) and the selling shareholder, Themis BeteiligungsAktiengesellschaft,\u00a0have set the offer price at EUR 28.00 per share. In total, all of the 13,455,000 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":98872,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[221,90],"tags":[225],"class_list":["post-18812","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-ad-hoc-news","category-news-en","tag-2018-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.2 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share - cometis AG<\/title>\n<meta name=\"description\" content=\"Dermapharm Holding SE: legt Angebotspreis auf 28,00 Euro je Aktie fest\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share\" \/>\n<meta property=\"og:description\" content=\"Dermapharm Holding SE: legt Angebotspreis auf 28,00 Euro je Aktie fest\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-08T16:53:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T12:28:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"171\" \/>\n\t<meta property=\"og:image:height\" content=\"31\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\"},\"headline\":\"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share\",\"datePublished\":\"2018-02-08T16:53:20+00:00\",\"dateModified\":\"2025-01-29T12:28:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/\"},\"wordCount\":819,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"keywords\":[\"2018\"],\"articleSection\":[\"Dermapharm Ad-Hoc News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/\",\"name\":\"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share - cometis AG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"datePublished\":\"2018-02-08T16:53:20+00:00\",\"dateModified\":\"2025-01-29T12:28:24+00:00\",\"description\":\"Dermapharm Holding SE: legt Angebotspreis auf 28,00 Euro je Aktie fest\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"width\":172,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"c-LEcta Corporate News\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/category\\\/c-lecta-corporate-news-en\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cometis-ag\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/cometisAG\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/author\\\/assistenz-cometis-ag\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share - cometis AG","description":"Dermapharm Holding SE: legt Angebotspreis auf 28,00 Euro je Aktie fest","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/","og_locale":"en_US","og_type":"article","og_title":"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share","og_description":"Dermapharm Holding SE: legt Angebotspreis auf 28,00 Euro je Aktie fest","og_url":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/","og_site_name":"cometis AG","article_published_time":"2018-02-08T16:53:20+00:00","article_modified_time":"2025-01-29T12:28:24+00:00","og_image":[{"width":171,"height":31,"url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/#article","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1"},"headline":"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share","datePublished":"2018-02-08T16:53:20+00:00","dateModified":"2025-01-29T12:28:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/"},"wordCount":819,"publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"image":{"@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","keywords":["2018"],"articleSection":["Dermapharm Ad-Hoc News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/","url":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/","name":"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share - cometis AG","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/#primaryimage"},"image":{"@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","datePublished":"2018-02-08T16:53:20+00:00","dateModified":"2025-01-29T12:28:24+00:00","description":"Dermapharm Holding SE: legt Angebotspreis auf 28,00 Euro je Aktie fest","breadcrumb":{"@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/#primaryimage","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","width":172,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/www.cometis.de\/en\/february-8-2018-dermapharm-holding-se-sets-offer-price-at-eur-28-00-per-share\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cometis.de\/en\/"},{"@type":"ListItem","position":2,"name":"c-LEcta Corporate News","item":"https:\/\/www.cometis.de\/en\/category\/c-lecta-corporate-news-en\/"},{"@type":"ListItem","position":3,"name":"February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share"}]},{"@type":"WebSite","@id":"https:\/\/www.cometis.de\/en\/#website","url":"https:\/\/www.cometis.de\/en\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cometis.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cometis.de\/en\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/www.cometis.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cometis-ag\/","https:\/\/www.youtube.com\/user\/cometisAG"]},{"@type":"Person","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/www.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/18812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=18812"}],"version-history":[{"count":0,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/18812\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media\/98872"}],"wp:attachment":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=18812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=18812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=18812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}